Combined immunotherapy improves survival in metastatic melanomaBMJ 2015; 350 doi: http://dx.doi.org/10.1136/bmj.h2993 (Published 02 June 2015) Cite this as: BMJ 2015;350:h2993
- Susan Mayor
A combination of two immunotherapy agents acting on different steps in activation of the immune system considerably improves the time to disease progression in patients with previously untreated metastatic melanoma when compared with either drug alone, first study to investigate this dual approach has shown.
The international study, reported in the New England Journal of Medicine,1 randomly assigned 945 patients with unresectable stage III or IV melanoma to treatment with either nivolumab alone, nivolumab plus ipilimumab, or ipilimumab alone.
Results showed that …
Log in using your username and password
Log in through your institution
Register for a free trial to thebmj.com to receive unlimited access to all content on thebmj.com for 14 days.
Sign up for a free trial